Published online Jul 21, 2021. doi: 10.3748/wjg.v27.i27.4383
Peer-review started: January 28, 2021
First decision: March 29, 2021
Revised: April 12, 2021
Accepted: July 5, 2021
Article in press: July 5, 2021
Published online: July 21, 2021
Core Tip: Neoadjuvant therapy (NT) is an increasingly utilized approach that maximizes the receipt of multimodality therapy, improves margin-negative resection rates, and potentially increases survival durations. In the era of personalized medicine, the neoadjuvant period can also be used to emphasize precision oncology. Already, current methods of anatomically staging, molecularly profiling, and monitoring response to therapy can be used to personalize neoadjuvant treatment for localized pancreatic ductal adenocarcinoma (PDAC). In this article, we describe the current evidence for the use of NT and highlight unique opportunities for personalized care in patients with PDAC undergoing NT.